Animal experimental studies have demonstrated that both anti‐HMGB1 antibody and glycyrrhiza sweetener injections can reduce the infarction volume (Chen et al., 2020; Liu et al., 2007; Xiong et al., 2016), indicating that HMGB1 released after cerebral infarction is mainly damaging. Here, HMGB1 is linked to brain infarction.